Fennec Pharmaceuticals Reports Record Q3 2026 Results with Significant EBITDA Growth
Fennec Pharmaceuticals (FENC) reported record-breaking financial results for the third quarter of 2026, characterized by a 56% year-over-year increase in net product sales to $19.4 million. The company demonstrated strong operating leverage, with Non-GAAP Adjusted EBITDA rising to $5.8 million from $2 million in the prior-year period, resulting in an improved margin of 30%. This growth was driven by a surge in patient enrollments and quarterly infusions, which rose 58% compared to the previous quarter. The company's strategic 'Project Ignite' expansion has successfully increased its target physician accounts from 1,300 to 5,000. Fennec maintains a robust balance sheet with $48.7 million in cash and zero debt. While management noted potential long-term timelines for commercializing PEDMARK in the Japanese market, the current focus remains on expanding clinical evidence for broader adult and metastatic patient populations.
Tickers: $FENC
Topics: Adjusted EBITDA Cash Flow Earnings Per Share Net Product Sales Patient Enrollments
Read the full article at Motley Fool
Part of the story Fennec Pharmaceuticals Reports Record Q3 2026 Results with Significant EBITDA Growth (2 articles)